The true breakthrough of the GLP-1 weight-loss market wasn't just consumer ads or cash payments. It was the creation of new distribution channels like direct-to-patient platforms (e.g., Lilly Direct) and the strategic use of telehealth, which created frictionless access to branded prescriptions.
Primary care physicians often learn about new consumer-focused drugs from repeated patient requests, not from pharma reps. A transparent, cash-pay option removes the friction of prior authorizations, making doctors more willing to prescribe a new medication they've just learned about from their patients.
The incumbent topical hair loss treatment has an estimated 86% discontinuation rate. Dermatologists anticipate this failure, often re-booking patients in three months expecting them to have given up and be ready for an oral alternative. This built-in product failure highlights a significant opportunity for a more convenient solution.
Large telehealth players have shifted from being a threat (via compounded drugs) to being a primary sales channel for branded pharmaceuticals. For new launches like Oral Wegovi, telehealth is now a major driver of prescriptions, demonstrating a crucial evolution where these platforms have become friends, not foes, to pharma companies.